tbuckley/cabot-search huggingface dataset:
Prise en charge endoscopique des complications biliaires après transplantation hépatique: étude rétrospective sur 57 cas
Authors: S Bonnefoy, B Ducot, O Scatton, Y Calmus, F Conti, PP Massault, M Gaudric, JC Duchmann, L Manglialavori, S Chaussade, O Soubrane, F Prat
Journal: Endoscopy (2011)

Introduction: L'incidence des complications biliaires après transplantation hépatique varie de 7 à 34%. Ces complications sont: des sténoses anastomotiques ou non anastomotiques, des fistules et des calculs biliaires, une dysfonction du sphincter d'Oddi. Elles influencent la survie des patients et des greffons. Leur prise en charge n'est pas standardisée, et aucune étude n'a comparé, de façon prospective et randomisée, les différentes techniques (chirurgicale, percutanée et endoscopique) à notre disposition pour les prendre en charge. Nous rapportons l'expérience de l'hôpital Cochin dans la prise en charge endoscopique de ces complications et tentons de mettre en évidence des facteurs prédictifs de succès ou d'échec du traitement endoscopique.
ASCO Gears Up to Control Its Own Destiny
Authors: H. McIntosh
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article ASCO Gears Up to Control Its Own Destiny Get access Hugh McIntosh Hugh McIntosh Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 87, Issue 22, 15 November 1995, Pages 1665–1666, https://doi.org/10.1093/jnci/87.22.1665 Published: 15 November 1995
BENEFICIAL EFFECT OF PLATELET INHIBITION AGAINST PERI-PROCEDURAL MYOCARDIAL INFARCTION DUE TO INTRA-STENT THROMBUS PENETRATION: OPTICAL COHERENCE TOMOGRAPHY SUB-ANALYSIS IN PRASFIT ELECTIVE
Authors: Kenzo Uzu, Toshiro Shinke, Hiromasa Otake, Tomofumi Takaya, Tsuyoshi Osue, Masamichi Iwasaki, Akihide Konishi, Hiroto Kinutani, Masaru Kuroda, Hachidai Takahashi, Daisuke Terashita, Ken-ichi Hirata, Shigeru Saito, Masato Nakamura, Junya Shite, Takashi Akasaka
Journal: Journal of the American College of Cardiology (2015)
Abstract 335: Mutation analysis of KRAS and BRAF genes in sebaceous lesions and keratoacanthomas sporadic or related to hereditary syndrome
Authors: Sibele I. Meireles, Merin B. Stamboni, Rodrigo Crespo, Marina Gomes, Gilles Landman, Renata A. Coudry
Journal: Cancer Research (2011)

Abstract BACKGROUND: Sebaceous lesions comprises: hyperplasias, adenomas, sebaceomas and carcinomas, which can be sporadic or related to hereditary syndrome. Keratoacanthomas, as sebaceous lesions, can be associated with hereditary cancer, known as Muir-Torre syndrome (MTS), accepted as the presence of those lesions with visceral malignancies, mainly colorectal cancer (CRC). Besides, a subset of MTS shares clinical, pathological and molecular characteristics with hereditary nonpolyposis colorectal cancer (HNPCC). BRAF mutation has already been described in sebaceous hyperplasia but not in CRC in an onset of HNPCC. BRAF oncogene is part of the MAPKinase pathway, as KRAS gene, and both have an important role in cellular proliferation, differentiation and apoptosis. OBJECTIVE: The aim of this study was to evaluate the role of KRAS and BRAF genes in sebaceous lesions and keratoacanthomas in a sporadic setting or related with hereditary syndrome. METHODS: KRAS (codons 12 and 13) and BRAF (V600E) mutations of 52 sebaceous lesions and 42 keratoacanthomas samples was evaluated using Sanger sequencing. 24 (46%) patients had at least one internal malignancy and thus were diagnosed as having MTS. 7 (14%) patients presented clinical or molecular diagnosis of HNPCC. RESULTS: Mutations in KRAS was identified in 7 of 52 cases (14%) of sebaceous lesions and 10 of 42 cases (24%) of keratoacanthomas. BRAF mutation was observed in 2 of 52 cases (4%) of sebaceous lesions and 2 of 42 cases (5%) of Keratoacanthomas. Mutation in both genes occurred in just one sample. There was no statistical significance observed with clinical variables. BRAF mutation was not observed in patients with diagnosis of MTS or HNPCC. CONCLUSION: The results indicate that KRAS and BRAF mutations play a distinct role in carcinogenesis of sebaceous lesions and KRAS a more important event in keratoacanthomas. KRAS mutation was observed in sporadic lesions and also related to hereditary syndrome. However, BRAF mutation was not observed in patients with HNPCC, concordant with observed in CRC with the same origin. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 335. doi:10.1158/1538-7445.AM2011-335
Abstract 337: HPV16 infection plays a significant role in laryngeal carcinogenesis among Puerto Ricans
Authors: Germán L. Vélez-Reyes, Francisco J. Ruiz-Fullana, Aurian García, Juan Trinidad-Pinedo, Adriana Baez
Journal: Cancer Research (2011)

Abstract Aims: Incidence of head and neck cancer (HNSCC) has increased in the past decades in younger adults. Oncogenic proteins E6 and E7 in HPV 16 are known to block the p53 and pRB pathways leading to abnormal cell growth and development of cancer. We have shown that human papillomavirus type 16 (HPV-16) plays a significant role in the etiology of head and neck cancer in the Puerto Rican population. Furthermore, there is an increasing trend in the incidence of oropharyngeal cancers, particularly among men under 50 years old, for which HPV infection is the likely cause. This study aims to evaluate the association between clinicopathologic and demographic characteristics of HPV16- positive HNSCC Puerto Rican patients. Methodology: Clinical and pathological data of all newly diagnosed cancer patients was collected, after signing the informed consent. The distribution by anatomical site was as follows: 86 larynx, 16 oropharynx, 12 hypopharynx, and 70 in the oral cavity. Detection and quantification of HPV16 E6 oncoproteins in tumor tissue was made by real time PCR technology. Associations between HPV status, risk factors and tumor characteristics were analyzed. Results: HPV16 was found in 52% of tumors tested. When the HNSCCs were analyzed by anatomical site for HPV-status, 52% of the larynx, 53% of oral cavity, 62% of oropharynx, and 42% of the hypopharynx were HPV-positive. The highest prevalence was observed in patients under the age of 60 years. No significant association was found between HPV status and histological grade, alcohol usage, and smoking status. Conclusions: Our results suggest that the high HPV DNA present in laryngeal HNSCCs indicates that HPV16 has significant role in the development of SCC of the larynx in Puerto Ricans. These results may be further validated in a larger sample of patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 337. doi:10.1158/1538-7445.AM2011-337
TMIC-11NOVEL ANGIOCRINE CANDIDATES IN GLIOBLASTOMA PROGENITOR CELL PERIVASCULAR NICHE INTERACTIONS
Authors: Yasmin Ghochani, Riki Kawaguchi, Giovanni Coppola, Harley Kornblum
Journal: Neuro-Oncology (2015)

Glioblastoma (GBM) cells promote and rely on tumor-associated vessels that form a structurally and functionally aberrant microvascular environment contributing to pathology, malignancy, and clinical prognosis.Self-renewing and multipotential tumor progenitor cells (TPCs) reside in close association with this microvasculature, which maintains them in a stem-like state.However, the factors responsible for this maintenance are still unknown.Given their contribution to normal vasculature, we examined the role of tumor associated endothelial cells (ECs) on GBM progression.We found Overall survival
MYOCARDIAL FIBROSIS FOLLOWING ISCHEMIA AND INFARCTION IS GREATER AMONG PERSONS WITH HUMAN IMMUNODEFICIENCY VIRUS THAN UNINFECTED CONTROLS
Authors: Matthew Feinstein, Sumeet Mitter, Ajay Yadlapati, Mark Gajjar, Chad Achenbach, Frank Palella, Jeremy Collins, Donald Lloyd-Jones
Journal: Journal of the American College of Cardiology (2016)
OC-055 Ibd Passport-developing An Evidence-based Internet Travel Resource For Inflammatory Bowel Disease: A Report Of The Initial Stages Of Implementation
Authors: K Greveson, TC Shepherd, MI Hamilton, C Murray
Journal: Gut (2014)

<h3>Introduction</h3> Travellers with Inflammatory bowel disease (IBD) are at greater risk of travel-related morbidity <sup>[1]</sup>,with ECCO recommending expert consultation prior to travel, particularly for those on immunosuppression<sup>.2</sup> The travel consult and patients pre-travel preparation have been found to be deficient<sup>.1</sup> Here we present the development of a dedicated IBD travel advice website to enable informed, safe travel with IBD. <h3>Methods</h3> We conducted a literature review using Ovid databases and a search of existing online material using major internet search engines to identify existing research and resources regarding IBD and travel. Data was extracted from a recently reported prospective survey<sup>3</sup> of 136 IBD patients which examined pre-travel preparation and experiences of travelling with IBD. <h3>Results</h3> The database and Internet search revealed a paucity of research and resources available for IBD patients and professionals regarding travel and IBD. Our survey of 136 patients found 60% [82/136] reported IBD affected travel, however; pre-travel medical advice was only sought by 24% [32/136]. Disease-related travel knowledge was poor with 52% of immunosuppressed patients unaware of the need to avoid live vaccines; only 53/136 (39%) buy travel insurance covering their IBD and the majority of these (70%) pay a premium. 91% (124/136) would find a dedicated IBD travel website useful. As a result of this, IBDPassport™ was developed for both patients and professionals as non-commercial, IBD-specific travel resource, aimed at providing evidence-based information on all aspects of travel and IBD. The functionality of the website includes an interactive map of country specific advice including vaccinations and a ‘search and refer’ service for IBD professionals to refer to other IBD centres globally. Features also include practical information for travelling with IBD and specific information for the immunocompromised traveller. <h3>Conclusion</h3> We present the first comprehensive web-based travel resource created for both IBD patients and professionals to obtain evidence-based IBD and country specific travel information. IBDPassport™ needs to be formally evaluated by patients and healthcare professionals as part of a larger study and to inform further development. <h3>References</h3> 1 Rahir <i>et al</i>. <i>ECCO</i> 2009 2 Soonawala <i>et al</i>. <i>Inflamm Bowel Dis</i> 2012 3 Greveson <i>et al</i>. A Recent Flare of Disease does not Prohibit Travel: Early Results of a Single Centre Study in Inflammatory Bowel Disease and Travel. Abstract Number: A-1908. ECCO 9<sup>th</sup> congress Copenhagen 2014 <h3>Disclosure of Interest</h3> None Declared.
Axing legal aid for clinical negligence claims will cost the NHS an extra 28.5m a year, says report
Authors: C. Dyer
Journal: BMJ (2012)

The UK government’s plans to scrap legal aid for clinical negligence claims in England and Wales will cost nearly three times as much as it saves and produce a net loss of £18m (€22m, $28m) a year, says an independent report from King’s College London.

The Legal Aid, Sentencing and Punishment of Offenders Bill, now in its committee stage in the House of Lords, will withdraw legal aid from a range of civil claims, including clinical negligence, in a bid to save £350m a year.

The government estimates that axing aid for clinical negligence claims would save the ministry of justice £10.5m a year. But the report, commissioned by the Law Society from …
Abstract 5385: Gene expression changes downstream of APC loss predict tumor phenotype.
Authors: Andjela Pehar, Jennifer M. Cole, Jenifer R. Prosperi
Journal: Cancer Research (2013)

Abstract The Adenomatous Polyposis Coli (APC) tumor suppressor is mutated or hypermethylated in up to 70% of human breast cancer cases. Our previous studies demonstrated that Apc mutation advances the MMTV-Polyoma Middle T Antigen (PyMT) model of breast cancer, with an increase in signaling downstream of focal adhesion kinase (FAK)/Src/JNK activation in MMTV-PyMT;ApcMin/+ tumors. In addition, the majority of tumors that arose in the MMTV-PyMT;ApcMin/+ animals were classified as adenosquamous carcinoma as compared to tumors from MMTV-PyMT;Apc+/+ animals, which were solid carcinomas. Given the heterogeneous nature of these tumors, laser capture microdissection (LCM) of the adenosquamous carcinoma in MMTV-PyMT;ApcMin/+ tissues followed by quantitative real-time RT-PCR was performed to identify gene expression changes responsible for the altered tumor phenotype. In parallel studies, gene expression microarrays were performed using triplicate samples of the MMTV-PyMT;Apc+/+ and MMTV-PyMT;ApcMin/+ cell lines. RNA samples were subjected submitted to quality control via the Agilent Bioanalyzer and were hybridized to Affymetrix Mouse Genome 430 2.0 microarrays. Data analysis was performed using the Gene-Go software, and significant changes were confirmed using qRT-PCR. Multiple changes consistent with the phenotypic and proliferative changes downstream of APC loss were identified, including changes in expression of cyclooxygenase-2 (COX-2). The findings presented here indicate that APC-mediated gene expression changes can be used to predict tumor phenotype and downstream therapeutic targets. Citation Format: Andjela Pehar, Jennifer M. Cole, Jenifer R. Prosperi. Gene expression changes downstream of APC loss predict tumor phenotype. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5385. doi:10.1158/1538-7445.AM2013-5385 Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend.
P202 Risk Factors For Early Mortality After Lung Cancer Resection: A Study of the UK National Lung Cancer Audit: Abstract P202 Table 1
Authors: HA Powell, LJ Tata, DR Baldwin, A Khakwani, R Stanley, RB Hubbard
Journal: Thorax (2012)

<h3>Introduction</h3> Surgical resection is the best chance of cure for most patients with non-small cell lung cancer (NSCLC), for whom 5-year survival is otherwise poor. Selection of patients for surgery should include an estimation of the likely post-operative mortality risk but the tool often used in UK practise is a predictive score that was developed using a French database of thoracic surgical procedures, not specific to lung cancer. <h3>Methods</h3> We used data from the National Lung Cancer Audit linked with Hospital Episode Statistics to estimate the influence of pre-operative patient and tumour factors, and the type of procedure on the odds of death at 30 and 90 days after potentially curative surgery for NSCLC. We used logistic regression to determine which factors were associated with early post-operative mortality and then calculated the percentage of patients who died within 90 days of surgery, stratified by the strongest predictors of early post-operative mortality. <h3>Results</h3> We identified 12,096 patients who had potentially curative surgery for NSCLC in England between January 2004 and March 2010. Three per cent (n=387) and 6% (n=792) of patients died within 30 and 90 days respectively. Of the 12 clinical and socio-demographic factors assessed, age and type of procedure were consistently the most important predictors of early post-operative mortality: Odds ratio (OR) for death at 30 days for pneumonectomy compared with lobectomy 3.03, 95% confidence interval (CI) 2.32–3.94; and for each year increase in age OR 1.06, 95% CI 1.04–1.07. Performance status, co-morbidity score and sex and were also significantly associated with the outcomes. Table 1 shows the percentage of patients who died within 90 days of either lobectomy or pneumonectomy, stratified by age and performance status. <h3>Conclusion</h3> The estimation of post-operative mortality risk is a crucial part of management of patients with NSCLC. Overall mortality following surgery for NSCLC in England is currently 3% at 30-days and 6% at 90-days. We present UK data, stratified by age and performance status, which could be used in clinical practise to assist with the estimation of early post-operative mortality risk.
Valuation of pemphigus vulgaris and pemphigus foliaceus health states: a convenience sample experiment
Authors: F. Rencz, V. Brodszky, P.F.M. Stalmeier, B. Tamási, S. Kárpáti, M. Péntek, P. Baji, A.Z. Mitev, L. Gulácsi
Journal: British Journal of Dermatology (2016)

Health‐related quality of life (HRQoL) in pemphigus has been widely investigated; nevertheless, utility values for economic evaluations are still lacking. To estimate health utilities for hypothetical pemphigus vulgaris (PV) and pemphigus foliaceus (PF) health states in a general population sample. Three health states (uncontrolled PV, uncontrolled PF and controlled pemphigus) were developed based on a systematic literature review of HRQoL studies in pemphigus. Utilities were obtained from a convenience sample of 108 adults using a visual analogue scale (VAS) and 10‐year time trade‐off (TTO). Lead‐time TTO was applied for health states regarded as worse than dead with a lead time to disease time ratio of 1 : 1. The mean VAS utility scores for PV, PF and controlled pemphigus were 0·25 ± 0·15, 0·37 ± 0·17 and 0·63 ± 0·16, respectively. Corresponding TTO utilities were as follows: 0·34 ± 0·38, 0·51 ± 0·32 and 0·75 ± 0·31. Overall, 14% and 6% judged PV and PF as being worse than dead. For both VAS and TTO values, significant differences were observed between all health states (P < 0·001). VAS utilities were rated significantly lower compared with TTO in each health state (P < 0·001). This is the first study that reports health utility values for PV and PF. Successful treatment of pemphigus might result in significant utility gain (0·24–0·41). These empirical findings with respect to three health states in pemphigus may serve as anchor points for further utility studies and cost‐effectiveness analyses.
Abnormal Histamine-Induced Suppressor-Cell Function in Atopic Subjects
Authors: Dennis J. Beer, Michael E. Osband, Ronald P. McCaffrey, Nicholas A. Soter, Ross E. Rocklin
Journal: New England Journal of Medicine (1982)

To detect a potential defect in immunoregulatory function in atopic subjects, we studied histamine-induced suppressor-T-cell activity and histamine Type 1 and Type 2 receptors on T cells. Peripheral-blood mononuclear cells from 16 atopic subjects generated less histamine-induced suppressor activity than did those from 20 nonatopic normal controls (P<0.005). The percentage of T lymphocytes bearing histamine Type 2 receptors was lower in the atopic group than in the control group (P<0.001), but the percentage of cells with Type 1 receptors was the same in both groups. In the atopic subjects, the functional suppressor-cell abnormality positively correlated with the decreased phenotypic expression of histamine Type 2 receptors. No abnormality in concanavalin A-induced suppressor activity was detected in these subjects. Nonatopic control subjects with systemic mastocytosis had normal functional and phenotypic data, suggesting that chronic activation of atopic T cells in vivo by circulating histamine does not explain the abnormal histamine-induced suppressor response. (N Engl J Med. 1982; 306:454–8.)
Common variable immunodeficiency diagnosed by capsule endoscopy
Authors: K. Theede, M. Thiele, E. Langholz
Journal: Endoscopy (2011)

Common variable immunodeficiency (CVID) is the most frequent primary immunodeficiency, characterized by reduced levels of immunoglobulins [1] [2]. Due to a heterogeneous presentation including a heightened rate of infections, the diagnosis is often delayed for 4 – 9 years. This delay may contribute to the increased morbidity and mortality in CVID patients [1] [3].
Recruitment of New Physicians, Part I
Authors: Jay A. Harolds
Journal: Clinical Nuclear Medicine (2013)

Organizations are judged largely by the quality of their people and their output. It is therefore critical to obtain the best possible new physicians in the recruiting process. However, getting the finest doctor for the job may mean looking for someone who brings more than expertise in a subspecialty field such as nuclear medicine. The group doing the hiring may also want an individual who has expertise in business, leadership, computers, or other areas. It may be the group wants someone who is a star in research or teaching or whose name is recognized internationally. Other groups may want someone who is very fast or is prepared to take much call. It is also important to pick a person who will be happy in the location and practice, and get along well with other people.
Combined Administration of 5-Fluorouracil as Well as 2-Oxohexyl Isothiocyanate with Selol Gives Synergistic Toxic Effect on HT -29 Colorectal Cancer Cell Lines
Authors: Śliwka Lidia, Lubelska Katarzyna, Milczarek Małgorzata, Mielczarek Szymon, Gilbert Anna, Flis Anna, Suchocki Piotr, Wiktorska Katarzyna
Journal: Annals of Oncology (2014)
Hematopoietic Stem-Cell Transplantation for the Treatment of Severe Combined Immunodeficiency
Authors: Rebecca H. Buckley, Sherrie E. Schiff, Richard I. Schiff, M. Louise Markert, Larry W. Williams, Joseph L. Roberts, Laurie A. Myers, Frances E. Ward
Journal: New England Journal of Medicine (1999)

Since 1968 it has been known that bone marrow transplantation can ameliorate severe combined immunodeficiency, but data on the long-term efficacy of this treatment are limited. We prospectively studied immunologic function in 89 consecutive infants with severe combined immunodeficiency who received hematopoietic stem-cell transplants at Duke University Medical Center between May 1982 and September 1998.Serum immunoglobulin levels and lymphocyte phenotypes and function were assessed and genetic analyses performed according to standard methods. Bone marrow was depleted of T cells by agglutination with soybean lectin and by sheep-erythrocyte rosetting before transplantation.Seventy-seven of the infants received T-cell-depleted, HLA-haploidentical parental marrow, and 12 received HLA-identical marrow from a related donor; 3 of the recipients of haploidentical marrow also received placental-blood transplants from unrelated donors. Except for two patients who received placental blood, none of the recipients received chemotherapy before transplantation or prophylaxis against graft-versus-host disease. Of the 89 infants, 72 (81 percent) were still alive 3 months to 16.5 years after transplantation, including all of the 12 who received HLA-identical marrow, 60 of the 77 (78 percent) who were given haploidentical marrow, and 2 of the 3 (67 percent) who received both haploidentical marrow and placental blood. T-cell function became normal within two weeks after transplantation in the patients who received unfractionated HLA-identical marrow but usually not until three to four months after transplantation in those who received T-cell-depleted marrow. At the time of the most recent evaluation, all but 4 of the 72 survivors had normal T-cell function, and all the T cells in their blood were of donor origin. B-cell function remained abnormal in many of the recipients of haploidentical marrow. In 26 children (5 recipients of HLA-identical marrow and 21 recipients of haploidentical marrow) between 2 percent and 100 percent of B cells were of donor origin. Forty-five of the 72 children were receiving intravenous immune globulin.Transplantation of marrow from a related donor is a life-saving and life-sustaining treatment for patients with any type of severe combined immunodeficiency, even when there is no HLA-identical donor.